Roche Elecsys Anti-SARS-CoV-2 S (Spike Antibody)

 by 

Immunosciences Lab

The Long COVID Panel is used to detect three major viruses (EBV, HHV-6, and SARS-CoV-2) associated with long COVID and autoimmunity. It has been found that increased levels of antibodies against EBV and HHV-6 correlate with the severity of long COVID.

 by 

Immunosciences Lab

This panel measures antibodies against six different viruses (EBV, CMV, HSV-1, HSV-2, HHV-6, VZV) that are involved in different inflammatory autoimmune diseases, chronic fatigue syndrome or myalgic encephalitis, neurodegenerative disorders such as Alzheimer’s and Parkinson’s, and neurological disorders such as Guillain-Barré syndrome and multiple sclerosis. Reactivation of these viruses is a major driver in increasing the severity of symptoms in patients with COVID-19. The test confirms immunological memory against Varicella zoster (VZV), the causative agent for shingles.

 by 

Immunosciences Lab

This panel measures antibodies against seven different viruses (EBV, CMV, HSV-1, HSV-2, HHV-6, VZV, measles) that are involved in different inflammatory autoimmune diseases, chronic fatigue syndrome or myalgic encephalitis, neurodegenerative disorders such as Alzheimer’s and Parkinson’s, and neurological disorders such as Guillain-Barré syndrome and multiple sclerosis. Reactivation of these viruses is a major driver in increasing the severity of symptoms in patients with COVID-19. The test confirms immunological memory against Varicella zoster (VZV), the causative agent for shingles, and against Rubeola, the causative agent for measles.

 by 

Labcorp

This test looks for antibodies that indicate a recent or prior infection with COVID-19.

 by 

Immunosciences Lab

This screen detects chronic and ongoing infection with four major herpes viruses (EBV, CMV, HSV-1, HSV-2) that are involved in different inflammatory autoimmune and neurodegenerative disorders such as Alzheimer’s and Parkinson’s, and neurological disorders such as Guillain-Barré syndrome and multiple sclerosis. Reactivation of these viruses is a major driver in increasing the severity of symptoms in patients with COVID-19.